Song Yang, Wang Fei, Huang Qi, Cao Yan, Zhao Yingying, Yang Changqing
Division of Gastroenterology and Hepatology, Digestive Disease Institute, Shanghai Tongji Hospital, Tongji University School of Medicine, 389 Xin Cun Road, Shanghai 200065, China.
Mini Rev Med Chem. 2015;15(6):459-66. doi: 10.2174/1389557515666150324125353.
Hepatocellular carcinoma is a leading unnatural death worldwide, and it causes second most common cancer related death. Hepatocellular carcinoma development is distinct from other types of cancer, which is usually based on hepatic cirrhosis resulted from various etiologies including viral hepatitis, non-alcoholic liver diseases and alcohol abuse. MicroRNAs (miRNAs) are a group of small, non-coding sequences with approximate 20~ bp in length, which post-transcriptionally regulates target genes to control multiple biological activities. Recent studies have indicated that miRNAs contribute to hepatocellular carcinoma, indicating that targeting miRNAs might be a novel therapeutic strategy for the management of hepatocellular carcinoma. In this review, we summarized recent advances in the role of miRNAs in hepatocellular carcinoma, and also discussed the potential therapeutic and prognostic values of miRNAs in hepatocellular carcinoma.
肝细胞癌是全球主要的非自然死亡原因之一，也是导致癌症相关死亡的第二大常见原因。肝细胞癌的发展与其他类型的癌症不同，它通常基于由各种病因引起的肝硬化，这些病因包括病毒性肝炎、非酒精性肝病和酒精滥用。微小RNA（miRNA）是一组长度约为20个碱基对的小非编码序列，它们在转录后调节靶基因以控制多种生物学活性。最近的研究表明，miRNA与肝细胞癌的发生有关，这表明靶向miRNA可能是治疗肝细胞癌的一种新策略。在这篇综述中，我们总结了miRNA在肝细胞癌中作用的最新进展，并讨论了miRNA在肝细胞癌中的潜在治疗和预后价值。
